

AVV es similar al de las mujeres sin una historia de cáncer. [Nivel B]

- TE vaginal u ospemifeno, con vigilancia clínica adecuada, se pueden continuar, siempre y cuando los síntomas molestos estén presentes. [Nivel C]
- Se recomienda la educación preventiva en la salud vaginal para las mujeres posmenopáusicas. [Nivel C]

Conflicto de interés

No hay conflicto de intereses.

Referencias

- Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. *J Clin Endocrinol Metab* 2006;91:3791-3797.
- Schmidt G, Andersson SB, Nordle O, Johansson CJ, Gunnarsson PO. Release of 17-beta-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. *Gynecol Obstet Invest* 1994;38:253-260.
- Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. *Am J Obstet Gynecol* 2002;186:944-947.
- Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. *Menopause* 2002;9: 179-187.
- Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. *Obstet Gynecol* 2002;99:556-562.
- Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. *Climacteric* 2010;13:219-227.
- Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. *N Engl J Med* 1978;298:195-197.
- Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. *Obstet Gynecol* 1994; 84:215-218.
- Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? *Cancer Epidemiol Biomarkers Prev* 2007; 16:1713-1719.
- Fischer G, Bradford J. Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. *J Low Genit Tract Dis* 2011;15:263-267.
- Dennerstein GJ, Ellis DH. Oestrogen, glycogen and vaginal candidiasis. *Aust N Z J Obstet Gynaecol* 2001;41:326-328.
- Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. *Climacteric* 2010;13:228-237.
- Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. *Obstet Gynecol* 2008;112:1053-1060.
- Obiorah I, Jordan VC. 2012 NAMS/PfizerVWulf H. Utian Endowed Lecture. Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. *Menopause* 2013;20:372-382.
- Mastaglia SR, Bagur A, Royer M, Yankelevich D, Sayegh F, Oliveri B. Effect of endogenous estradiol levels on bone resorption and bone mineral density in healthy postmenopausal women: a prospective study. *Climacteric* 2009;12:49-58.
- Bagur A, Oliveri B, Mautalen C, et al. Low levels of endogenous estradiol protect bone mineral density in young postmenopausal women. *Climacteric* 2004;7:181-188.
- Cicinelli E, Di Naro E, De Ziegler D, et al. Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety. *Am J Obstet Gynecol* 2003;189:55-58.
- Tourgeman DE, Boostanfar R, Chang L, Lu J, Stanczyk FZ, Paulson RJ. Is there evidence for preferential delivery of ovarian estradiol to the endometrium? *Fertil Steril* 2001;75: 1156-1158.

107. Fanchin R, De Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. *Obstet Gynecol* 1997;90: 396-401.
108. Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Whitehead MI. Randomized, double-blind, dose-ranging study of endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. *Am J Obstet Gynecol* 1997;177:937-941.
109. De Ziegler D, Bulletti C, De Monstier B, Ja`a`skela`inen AS. The first uterine pass effect. *Ann N Y Acad Sci* 1997;828:291-299.
110. Winneker RC, Harris HA. Progress and prospects in treating postmenopausal vaginal atrophy. *Clin Pharmacol Ther* 2011;89:129-132.
111. Biglia N, Peano E, Sgandurra P, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. *Gynecol Endocrinol* 2010;26:404-412.
112. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. *Ann Oncol* 2006;17:584-587.
113. Col NF, Kim JA, Chlebowski RT. Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. *Breast Cancer Res* 2005;7:R535-R540.
114. Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. *Breast Cancer Res Treat* 2012;135:603-609.
115. Wills S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. *J Oncol Pract* 2012;8:144-148.
116. Estrace cream [package insert]. Rockaway, NJ: Warner Chilcott, LLC, 2011.
117. Premarin vaginal cream [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, 2012.
118. Estragyn vaginal cream [product monograph]. Concord, Ontario, Canada: Triton Pharma Inc, 2010.
119. Estring [package insert]. New York: Pharmacia & Upjohn Co, 2008.
120. Femring [package insert]. Rockaway, NJ: Warner Chilcott Inc, 2005.
121. Vagifem [package insert]. Princeton, NJ: Novo Nordisk Inc, 2012.
122. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of lowdose regimens of conjugated estrogens cream administered vaginally. *Menopause* 2009;16:719-727.
123. American Association of Sexuality Educators, Counselors and Therapists (AASECT) www.aasect.org.
124. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. *Obstet Gynecol* 2010;116:876-883.
125. Johnston SL, Farrell SA, Bouchard C, et al; SOGC Joint Committee-Clinical Practice Gynaecology and Urogynaecology. The detection and management of vaginal atrophy. *J Obstet Gynaecol Can* 2004;26:503-515.
126. American College of Obstetricians and Gynecologists Women's Health Care Physicians. Genitourinary tract changes. *Obstet Gynecol* 2004; 104(suppl 4):56S-61S.
127. Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. *Menopause* 2013;20:623-630.
128. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. *Menopause* 2010;17:480-486.
129. Simon JA, Lin VH, Radovich C, Bachmann GA; The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. *Menopause* 2013;20:418-427.
130. Osphena [package insert]. Florham Park, NJ: Shionogi Inc, 2013.
131. Wurz GT, Soe LH, Degregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer [published online ahead of print January 15, 2013]. *Maturitas* doi 10.1016/j.maturitas.2012.12.002.

132. Vogel VG, Costantino JP, Wickerham DL, et al.; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2727-2741. Erratum in: *JAMA*. 2007;298(9):973; *JAMA*. 2006;296(24):2926.
133. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2742-2751. Erratum in: *JAMA*. 298(9):973.
134. Davies GC, Huster WJ, Lu Y, Plouffe L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. *Obstet Gynecol* 1999;93:558-565.
135. Parsons A, Merritt D, Rosen A, Heath H 3rd, Siddhanti S, Plouffe L Jr; Study Group on the Effects of Raloxifene HCI With Low-Dose Premarin Vaginal Cream. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. *Obstet Gynecol* 2003;101:346-352.
136. Pinkerton JV, Shifren JL, La Valle J, Rosen A, Roesinger M, Siddhanti S. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. *Menopause* 2003;10:45-52.
137. Stovall DW, Utian QWH, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. *Menopause* 2007;14(3 pt 1):510-517.
138. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Natl Cancer Inst* 1998;90:1371-1388.
139. Chollet JA. Update on alternative therapies for vulvovaginal atrophy. *Patient Preference Adherence* 2011;5:533-536.
140. Portman D, Moffett A, Kerber I, Drosman S, Somayaji V, Lee A. Vaginal effects of lasofoxifene and raloxifene: preliminary evidence suggests lasofoxifene, but not raloxifene, improves indices of vaginal health [abstract]. *Menopause* 2004;11:675. Abstract P-87.
141. LaCroix AZ, Powles T, Osborne CK, et al.; PEARL Investigators. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. *J Natl Cancer Inst* 2010;102:1706-1715.
142. Bachmann G, Gass M, Kagan R, Moffett A, Barcomb L, Symons J. Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM) improves dyspareunia in postmenopausal women with vaginal atrophy (VA) [abstract]. *Menopause* 2005;12:238. *Menopause*, Vol. 20, No. 9, 2013 901 NAMS POSITION STATEMENT
143. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. *Fertil Steril* 2009;92:1025-1038.
144. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. *Menopause* 2010;17:281-289.
145. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. *Menopause* 2009;16:907-922.
146. Labrie F, Archer D, Bouchard C, et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. *Gynecol Endocrinol* 2010;26:524-532.
147. Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosis. *Cochrane Database Syst Rev*. 2011;7:CD008240.
148. Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. *Oncologist* 2011;16:424-431.
149. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. *Climacteric* 2012;15:267-274.